Medicines Into the European Market
European Regulatory
Strategy
One market on paper. Thirty regulators in practice.
One market on paper. Thirty regulators in practice.
Europe rewards teams that plan for its structure and punishes teams that treat it as a single agency. The centralised procedure, the decentralised and mutual recognition routes, national filings, notified bodies, and the post-Brexit pathways each carry different timelines, costs, and negotiating dynamics. We embed senior European regulatory leaders who have run these procedures end to end, so the pathway decision is made deliberately and defended confidently: to your board, to your investors, and to the agencies themselves.
Centralised, decentralised, or national: the route chosen for your product and your markets.
The route you take sets your timeline, your reach, and how every future variation is filed. Picking it by habit instead of by fit is the most expensive mistake a European program makes.
A single EMA review yielding one authorisation valid across the entire EU. Mandatory for many innovative products, and the fastest route to the whole market at once.
Simultaneous national applications run through one reference member state, for a product not yet authorised anywhere.
An authorisation already held in one member state recognised by others, market by market.
A single-country authorisation through one national competent authority, on its own terms.
Centralised, decentralised, mutual recognition, or national — the route sets your timeline, reach, and every future filing.
What used to be a single European submission is now three: the EU, the United Kingdom, and Switzerland, each with its own authority, timeline, and legal representative. Sequenced well, they reinforce one another. Ignored, they fragment a launch.
The EU, the UK, and Switzerland, sequenced so each approval strengthens the next.
The EMA and the national authorities, via the route you chose. Still the centre of gravity, but no longer the whole map.
The MHRA on its own timeline, with its own procedures and access schemes, and a UK Responsible Person to name.
Swissmedic, outside the EU system entirely, with its own authorised representative and import requirements.
The pathway decision is the start, not the finish. Three disciplines carry a product from a first conversation with the agency to the years of upkeep that follow approval.
Advice, submission, and maintenance run as one European program, not three disconnected tasks.
EMA scientific advice and protocol assistance, plus national advice where it counts, engineered around questions that produce answers you can act on, rather than the vague replies a vague question earns.
A Marketing Authorisation Application built for the assessor reading it: findable, coherent, and internally consistent across every module, so the dossier is judged on its data and not its navigation.
A European authorisation begins a permanent maintenance obligation: variations for every meaningful change, renewals, safety updates, and the slow accumulation of national differences that has to be governed, not ignored.
Medical devices and diagnostics run a parallel European system of their own. See our EU MDR & IVDR practice for classification, notified bodies, and technical documentation.
Europe is learned by doing it, agency by agency. Your leads are senior European regulatory practitioners who have taken products through the centralised procedure, coordinated decentralised launches, and rebuilt filings for the UK and Switzerland after Brexit split the map.
We settle the procedure before anything else, because timeline, reach, and every future variation follow from it.
Fluent across the EMA and the national competent authorities, so a launch is coordinated rather than improvised.
The EU, the UK, and Switzerland run as one plan, so the three filings reinforce each other instead of colliding.
Scientific advice engineered to return commitments you can build on, not the vague replies vague questions earn.
A European strategy connects to devices, to the wider world, and to the submissions that carry it. These are the services it reaches for most.
The parallel European framework for medical devices and diagnostics: classification, notified bodies, and technical documentation.
Explore MDR & IVDR →How the European plan sequences with the FDA and the rest of the world into one coherent global program.
Explore Global →The MAA assembled, validated, and transmitted through the EU gateway and CESP, the way each authority expects.
Explore Publishing →Tell us where your program stands and which markets matter most. We'll match you with a senior European regulatory lead and respond within one business day. All inquiries are strictly confidential.
